Last26.61 -1.02 (-3.69%)
15.88 - 54.21
52 Week Range
Technical Indicators (Daily)
Iovance Biotherapeutics is a biopharmaceutical startup based in San Carlos, California. The company works to develop tumor-infiltrating lymphocyte therapies against cancer.
The consensus price target hints at a 49% upside potential for Iovance Biotherapeutics (IOVA). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earn...
Iovance Biotherapeutics officially opens its $125M cell therapy center at the Philadelphia Navy Yard
The center is the first dedicated to producing potentially life-saving cell therapies for patients with solid tumor cancers....
Iovance Biotherapeutics to Present Clinical Data for Tumor Infiltrating Lymphocyte (TIL) Cell Therapies Across Multiple Solid Tumors and Treatment Settings at the Society for Immunotherapy of Cancer’s (SITC) 36th Annual Meeting
Oral Presentation of Clinical Data for TIL in Combination with Pembrolizumab in Immune Checkpoint Inhibitor-Naïve Patients with Advanced Cancers Poster for LN-145 Monotherapy in Advanced, Immune Chec...
Iovance Biotherapeutics Celebrates Grand Opening of Iovance Cell Therapy Center (iCTC) in the Philadelphia Navy Yard
Ribbon Cutting to be Led by Patient Advocacy Organizations, Caregivers, and Key Stakeholders Largest and First Centralized, Scalable, State-of-the-Art Facility with the Potential to Manufacture TIL Ce...
Iovance Biotherapeutics Initiates Clinical Supply of Tumor-Infiltrating Lymphocyte (TIL) Cell Therapy Manufactured at Iovance Cell Therapy Center (iCTC)
First Patient Infused with TIL Cell Therapy Manufactured at iCTC SAN CARLOS, Calif., Sept. 23, 2021 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company...
Disclaimer: The data contained in Super Surge website is not necessarily real-time nor accurate and may differ from the actual market data. Prices, volumes, ratios, charts and indicators are indicative and not appropriate for trading purposes. Super Surge doesn't bear any responsibility for any trading losses you might incur as a result of using this data.